Vinidhra Sridharan, Ph.D.

Associate Director, Translational Science

Vinidhra Sridharan serves as Associate Director, Translational Medicine at K36 Therapeutics. She brings to this role over six years of extensive experience in translational medicine, cultivated at Celgene and Bristol Myers Squibb (BMS).

​

During her tenure at Celgene/BMS, Vinidhra made significant contributions to the advancement of reverse translational studies, preclinical, and clinical research within the multiple myeloma therapeutic area. Notably, her recent preclinical research on T-cell engagers was pivotal in the initiation of a collaborative clinical trial at BMS. Subsequently, she transitioned into a biomarker-focused role, where she leveraged her expertise to further the development of innovative therapies for multiple myeloma.

​

Vinidhra holds a Bachelor of Technology in Industrial Biotechnology from India and a Ph.D. in Cellular, Molecular, and Developmental Biology from the University of Kansas, Lawrence. She completed her postdoctoral research fellowship in the Protein Processing Section at the National Cancer Institute, NIH, Maryland.